Lilly Launches Lower-Priced Insulin Lispro
Eli Lilly has launched its authorized generic of its own Humalog (insulin lispro) brand in the US, at a 50% discount to the list price of the original.
You may also be interested in...
Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.
Eli Lilly has launched further lower-priced versions of its Humalog KwikPen insulin products.
With rebate reform efforts stalled, insulin manufacturer broadens efforts to lower prices through authorized generics, but PBMs may still like the big rebates they can get on the original brands.